Research programme: orally active thrombin inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC/Centocor

Drug Profile

Research programme: orally active thrombin inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC/Centocor

Alternative Names: JNJ 6368661; Orally active thrombin inhibitors research programme - 3-Dimensional Pharmaceuticals/Centocor

Latest Information Update: 11 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 11 Jul 2011 Discontinued - Preclinical for Thrombosis in USA (PO)
  • 22 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the pharmacokinetics and Thrombosis pharmacodynamics sections
  • 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top